Select Vaccines signs agreement to develop Hep C test
Thursday, 25 March, 2004
Select Vaccines (ASX: SLT) has signed a materials transfer agreement (MTA) with a multinational biotechnology company to access materials it will use to accelerate the development of its hepatitis C rapid diagnostic test.
"It's one in a series of MTAs which will put us in the best possible position to have a rapid test that works with a number of rapid systems in the marketplace," said CEO Dr Martin Soust.
Soust said the agreement would cut at least three months off the timeframe required to develop the point-of-care test, and would allow the company to compare multiple rapid systems concurrently.
The MTA also contains the provision that the supplier company will be able to exercise rights to license or on-license any IP that arises from successful development.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
